When to treat and the benefits of treating hepatitis C in patients with haemophilia

Haemophilia

Volumn 15, Issue 1, 2009, Pages 20-32

  Patel, H ^a   Heathcote, E Jenny ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Antiviral therapy; Cirrhosis; Haemophilia; Hepatic fibrosis; Hepatitis C

Indexed keywords

ALPHA INTERFERON; BLOOD CLOTTING FACTOR CONCENTRATE; ENZYME INHIBITOR; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN;

ALCOHOL CONSUMPTION; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER RISK; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DRUG TOLERABILITY; ERADICATION THERAPY; FLU LIKE SYNDROME; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MIXED INFECTION; PATIENT ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEX RATIO;

ADULT; AGED; ANTIVIRAL AGENTS; BLOOD TRANSFUSION; DISEASE PROGRESSION; HEMOPHILIA A; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; YOUNG ADULT;

EID: 63049086019     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01917.x     Document Type: Review

References (153)

1. Global Surveillance and control of hepatitis C. Report of WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Belgium. J Viral Hepatol 1999; 6: 35-47.
2. Seef LB, Hoofnagle JH. Appendix: The National Institute of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7: 261-87.
3. Martinez-Bauer E, Forns X, Armelles M et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008; 48: 20-7.
4. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
5. Remis R. A Study to Characterize the Epidemiology of Hepatitis C in Canada, 2002. Final Report. 2004. Ottawa: Health Canada. http://www.phacaspc.gc.ca/hepc/pubs/hepc2002/index-eng.php (last accessed on 28 April 2008).
6. Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990; 76: 254-6.
7. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-51.
8. Makris M, Preston FE, Triger DR et al. Hepatitis C antibody and chronic liver disease in hemophilia. Lancet 1990; 335: 1117-9.
9. Troisi CL, Hollinger FB, Hoots WK et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412-8.
10. World Federation of Haemophilia. 2006 WFH Global Survey, 2006. http://www.wfh.org/index.asp?lang=EN.
11. Arnold DM, Julian JA, Walker IR, Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21years of follow-up. Blood 2006; 108: 460-4.
12. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. 2004: 1-33.
13. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in hemophiliacs. Br J Haematol 1996; 94: 746-52.
14. Telfer P, Sabin C, Devereux H et al. The progression of HCV-associated liver disease in cohort haemophilic patients. Br J Haematol 1994; 87: 555-61.
15. Plug I, Van Der Bom JG, Peters M et al. Mortality and causes of death in patients with hemophilia, 1992-2001: A prospective cohort study. J Thromb Haemost 2006; 4: 510-6.
16. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.
17. Telfer PT, Devereux H, Savage K et al. Chronic hepatitis C virus infection in haemophilic patients: Clinical significance of viral genotype. Thromb Haemost 1995; 74: 1259-64.
18. Roffi L, Ricci A, Ogliari C. Infection among multitransfused thalassemics from HCV genotypes in Northern Italy: A survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29: 701-6.
19. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia 2007; 13: 156-63.
20. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31: 80-3.
21. Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. J Hepatol 1999; 31: 65-70.
22. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37: 60-4.
23. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-8.
24. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
25. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
26. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Eng J Med 1999; 340: 1228-33.
27. Vogt M, Lay T, Frosner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.
28. Wiese M, Berr F, Lafrenz M, Porst H, Olsen V. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000; 32: 91-6.
29. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis; a National Heart, Lung and Blood Institute collaborative study. Hepatology 2001; 33: 455-63.
30. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
31. Thabut D, Le Calvez S, Thibault V et al. Hepatitis C in 6,865 patients 65yr or older: A severe and neglected curable disease? Am J Gastroenterol 2006; 101: 1260-7.
32. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ. 2004; 328: 983.
33. Shiffman ML, Diago M, Tran A et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-52.
34. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
35. Poynard T, Morra R, Halfon P et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
36. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-87.
37. Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
38. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatol 1998; 28: 562-7.
39. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors. Gastroenterology. 2008; 134: 1699-714.
40. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups, Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
41. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
42. Massard J, Ratziu V, Thabut D et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-24.
43. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
44. Deuffic-Burban S, Poynard T, Vallron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-22.
45. Wand J. Hepatocellular carcinoma and sex. N Engl J Med 2007; 357: 1974-6.
46. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-93.
47. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peg-interferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
48. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
49. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 700-6.
50. Aborsangaya KB, Dembinski I, Khatkar S, Alphonse MP, Nickerson P, Rempel JD. Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology 2007; 45: 623-30.
51. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-9.
52. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-5.
53. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: A meta-analysis. Clin Gastroenterol Hepatol 2005; 3: 1150-9.
54. Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-31.
55. Monto A, Patel K, Bostrom A et al. Risks of a range of alcohol intake on hepatitis C related fibrosis. Hepatology 2008; 39: 826-34.
56. Hwang SJ, Luo JC, Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-5.
57. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
58. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
59. Rubbia-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype-specific way. Gut 2004; 53: 406-12.
60. Matos CA, Perez CM, Pacheco MS et al. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol 2006; 21: 1236-9.
61. Fiore G, Fera G, Napoli N, Vella F, Schiraldi O. Liver steatosis and chronic hepatitis C: A spurious association? Eur J Gastroenterol Hepatol 1996; 8: 125-9.
62. Castéra L, Hézode C, Roudot-Thoraval F et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
63. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
64. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
65. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
66. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T, LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-55.
67. Muzzi A, Leandro G, Rubbia-Brandt L et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-6.
68. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
69. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
70. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62.
71. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
72. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-9.
73. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The multivirc group. Hepatology 1999; 30: 1054-8.
74. Goedert JJ, Eyster ME, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584-9.
75. Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors'Organisation. Lancet 1997; 350: 1425-31.
76. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602-10.
77. Pineda JA, García-García JA, Aguilar-Guisado M et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622-30.
78. Qurishi N, Kreuzberg C, Lüchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-12.
79. Lichterfeld M, Schmeisser N, Qurishi N et al. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect 2005; 50: 221-8.
80. Zarski JP, Bohn B, Bastie A et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
81. Chiaramonte M, Stroffolini T, Vian A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-7.
82. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
83. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-71.
84. Hézode C, Lonjon I, Roudot-Thoraval F et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52: 126-9.
85. El-Zayadi A, Selim O, Hamdy H et al. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 2004; 10: 2963-6.
86. Hézode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.
87. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases practice guideline: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
88. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
89. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
90. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
91. Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral response with peginterferon alpha-2a (40KD). J Hepatol 2002; 37: 500-6.
92. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 2008; 47: 1884-93.
93. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
94. Shiffman ML, Suter F, Bacon BR et al. Peginterferon Alfa-2a (40KD) Plus Ribavarin for 16 or 24 Wks in Patients with HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis. N Engl J Med 2007; 357: 124-34.
95. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCVinfection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004; 40: 1260-5.
96. Powis J, Peltekian KM, Lee SS et al. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008; 15: 52-7.
97. Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371-9.
98. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
99. Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. Abstract 7, J Hepatol 2008; 48: S5.
100. Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50.
101. Bronowicki JP, Ouzan D, Asselah T, Desmorat H et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 1040-8.
102. Mancuso ME, Rumi MG, Santagostino E et al. Hepatitis Study Group of the Association of Italian Hemophilia Centers. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006; 91: 1367-71.
103. Posthouwer D, Yee TT, Makris M et al. Antiviral therapy for chronic hepatitis C in patients with inheritedbleeding disorders: An international, multicenter cohort study. J Thromb Haemost. 2007; 5: 1624-9.
104. Witkos M, Yi QL, Heathcote J, Kapral MK, Krahn MD. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 2006; 20: 107-11.
105. Posthouwer D, Plug I, van der Bom JG et al. Hepatitis C infection among Dutch haemophilia patients: A nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005; 11: 270-5.
106. Shin JL, Teitel J, Swain MG et al. Virology and Immunology Committee of the Association of Hemophilia Clinic Directors of Canada. A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: Is it safe and useful?. Am J Hematol 2005; 78: 85-93.
107. Sterling RK, Lyons CD, Stravitz RT et al. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: Safety of outpatient procedure and impact of human immunodeficiency virus co-infection on the spectrum of liver disease. Haemophilia 2007; 13: 164-71.
108. Maor Y, Calès P, Bashari D et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007; 13: 722-9.
109. Rockstroh JK, Spengler U, Sudhop T et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563-8.
110. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-5.
111. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 783-5.
112. Garcia-Samaniego J, Bravo R, Castilla J et al. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 1998; 28: 526-7.
113. Fialaire P, Payan C, Vitour D et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1998; 177: 783-5.
114. Zeitoun JD, Mallet V, Chaix ML, Viard JP, Blanche S, Pol S. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. J Clin Virol 2007; 40: 71-3.
115. Martinez-Sierra C, Arizcorreta A, Díaz F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36: 491-8.
116. Neau D, Trimoulet P, Winnock M et al. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS 2001; 15: 1736-8.
117. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
118. Côté P, Baril J, Hébert M et al. Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Inf Dis Med Micro 2007; 18: 293-303.
119. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683-9.
120. Bruno R, Sacchi P, Filice G. Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo. AIDS 2003; 17: 2674-5.
121. Poynter ME, Daynes RA. Peroxysome proliferator-activated receptor an activation modulates cellular redox status, represses nuclear factor kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-41.
122. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-81.
123. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
124. Camma' C, Di Bona D, Schepis F et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.
125. Sherman M, Shafran S, Burak K et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007; 21: 25C-34C.
126. Zeuzem S, Diago M, Gane E et al. PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
127. Kevans D, Farrell G, Hopkins S et al. Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia 2007; 13: 593-8.
128. Pockros PJ, Shiffman ML, Schiff ER et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 1450-8.
129. Afdhal NH, Dieterich DT, Pockros PJ et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.
130. Koirala J, Gandotra SD, Rao S et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007; 14: 782-7.
131. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005; 39: S9-13.
132. McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.
133. Kraus MR, Schäfer A, Schöttker K et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: A randomized, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
134. Raison CL, Woolwine BJ, Demetrashvili MF et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-74.
135. Ahern M, Imperial J, Lam S. Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C. Gastroenterol Nurs 2004; 27: 149-55.
136. Ford JA, Cheong-Lee C. The role of hepatology nurse in the difficult-to-treat hepatitis C population. Can J Gastroenterol 2007; 21: 353-4.
137. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39: S23-7.
138. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
139. Buti M, San Miguel R, Brosa M et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.
140. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24: 97-104.
141. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005; 25: 72-83.
142. Gorbakov VV, Kim H, Oronsky B, Lang W. HCV RNA results from a phase II, randomized, open-label study of omega interferon (IFN) with or without ribavirin in IFN-näive genotype 1 chronic HCV patients. Hepatology 2005; 42: 705A.
143. Nelson D, Rustgi V, Balan V et al. A phase 2 study of albuferon in combination with ribavirin in non-responders to prior interferon therapy for chronic hepatitis C. Hepatology 2005; 42: 278A.
144. Osborn BL, Olsen HS, Nardelli B et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540-8.
145. Gish RG, Nelson D, Arora S et al. Virologic response and safety outcomes in therapy-näive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon-2a. J Hepatol 2005; 42: 39.
146. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77.
147. Jacobson IM, Everson GT, Gordon SC et al. Interim analysis results from a phase 2 study of telaprevir with peginterferon Alfa-2a and ribavirin in treatment-naïve subjects with Hepatitis C. Hepatology 2007; 47: Abstract 177.
148. Hezode C, Ferenci P, Dusheik GM, Pol S, Goeser T, Bronowicki J et al. PROVE2: Phase II study of Vx950 (Telaprevir) in combination with peginterferon Alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology 2007; 47: Abstract 80.
149. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson G, Fried MW et al. Robust synergistic antiviral effect of R1626 in combination with peginterferon Alfa-2a (40kd), with or without ribavirin - interim analysis results of phase 2a study. Analysis Hepatology 2007; 47: Abstract 167.
150. Pockros PJ, Patel K, O'Brien C et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003; 37: 1368-74.
151. Zabaleta A, Llopiz D, Arribillaga L et al. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol Ther 2008; 16: 210-7.
152. Tian Y, Zhang HH, Wei L et al. The functional evaluation of dendritic cell vaccines based on different hepatitis C virus nonstructural genes. Viral Immunol 2007; 20: 553-61.
153. Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134: 1385-95.